

*Reply and Amendment*

U.S. Serial No. 09/341,105

Attorney Reference: 015837-0275805

Page 10

101 caatataagt ggcttctcta ttccagcat gtttgaaga gcataaactc

151 aacagagtat atataaatct gatgtgaccc atgtcatctg ctacagcatg

201 agagggggta gtgac (SEQ ID NO: 19) --

IN THE CLAIMS:

Please cancel claims 2-9 and amend claim 1 as shown below:

-- 1. (Amended) An isolated Z-chromosomal DNA selected from the group consisting of Sequence 1 (43.Seq) (SEQ ID NO: 1), Sequence 2 (71.Seq) (SEQ ID NO: 2), Sequence 3 (80.Seq) (SEQ ID NO: 3), Sequence 4 (81.Seq) (SEQ ID NO: 4), Sequence 5 (131.Seq) (SEQ ID NO: 5), Sequence 6 (147.Seq) (SEQ ID NO: 6), Sequence 7 (166.Seq) (SEQ ID NO: 7), Sequence 8 (196.Seq) (SEQ ID NO: 8), Sequence 9 (199.Seq) (SEQ ID NO: 9), Sequence 10 (204.Seq) (SEQ ID NO: 10), Sequence 11 (235.Seq) (SEQ ID NO: 11), Sequence 12 (249.Seq) (SEQ ID NO: 12), Sequence 13 (258.Seq) (SEQ ID NO: 13), Sequence 14 (290.Seq) (SEQ ID NO: 14), Sequence 15 (309.Seq) (SEQ ID NO: 15), Sequence 16 (341.Seq) (SEQ ID NO: 16), Sequence 17 (398.Seq) (SEQ ID NO: 17), Sequence 18 (420.Seq) (SEQ ID NO: 18), and Sequence 19 (435.Seq) (SEQ ID NO: 19). --

REMARKS

This Reply is responsive to the final Office Action dated March 9, 2002. Entry of the foregoing and reconsideration on the merits pursuant to 37 CFR 1.112 is respectfully requested.

The application has been amended as set forth above. Marked-up versions of the amended text showing the changes that are made is attached hereto as an appendix.

The paragraph of the specification beginning at line 19 on page 5 is amended by capitalizing the product name "TWEEN-20," and by inserting its generic terminology, as called for in the Office Action dated March 9, 2002.